Skip to Content
Merck
CN

SML3632

NAQ

≥98% (HPLC)

Synonym(s):

17-Cyclopropylmethyl-3,14b-dihydroxy-4,5a-epoxy-6a-[(3’-isoquinolyl)acetamido]morphinan dihydrochloride, N-[(5α,6α)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-isoquinolinecarboxamide dihydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C30H31N3O4·2HCl
CAS Number:
1236037-13-0
Molecular Weight:
570.51
UNSPSC Code:
12352116
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Storage condition:
desiccated

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

SMILES string

O[C@]12[C@@]34C5=C(C[C@H]2N(CC4)CC6CC6)C=CC(O)=C5O[C@@]3([H])[C@H](CC1)NC(C7=CC8=C(C=CC=C8)C=N7)=O.[2HCl]

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Biochem/physiol Actions

Highly selective and high-affinity mu (μ) opioid receptor (MOR) antagonist in vitro and in vivo.




NAQ is a highly selective and high-affinity mu (μ) opioid receptor (MOR) antagonist with 241- & 48-fold selectivity over the delta (δ) and kappa (κ) opioid receptor, respectively (MOR/DOR/KOR Ki = 0.55/132.5/26.45 nM) and little MOR agonist activity (Emax = 15.83% of that of DAMGO by GTP[γS] binding using membrane from MOR-expressing cells). NAQ effectively antagonizes morphine antinociceptive effects in mice in vivo (warm-water tail immersion test AD50 = 0.45 mg/kg s.c. 5 min prior to 10 mg morphine/kg s.c.; no agonist efficacy up to 100 mg/kg).

Disclaimer

Hygroscopic

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000380457
0000380458
0000348909
0000348909
0000380457

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Kathryn L Schwienteck et al.
Neuropharmacology, 150, 200-209 (2019-01-21)
One emerging strategy to address the opioid crisis is the development of mu opioid receptor (MOR) ligands that preferentially signal the G-protein vs. β-arrestin pathway. The present study compared the relative potency and effectiveness of two G-protein biased (GPB)-MOR ligands
Yunyun Yuan et al.
Bioorganic & medicinal chemistry letters, 23(18), 5045-5048 (2013-08-21)
17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) was previously designed following the 'message-address' concept and was identified as a potent and highly selective mu opioid receptor (MOR) ligand based on its pharmacological profile. We here report the preliminary structure activity relationship (SAR) studies of this
Guo Li et al.
Journal of medicinal chemistry, 52(5), 1416-1427 (2009-02-10)
Opioid receptor selective antagonists are important pharmacological probes in opioid receptor structural characterization and opioid agonist functional study. Thus far, a nonpeptidyl, highly selective and reversible mu opioid receptor (MOR) antagonist is unavailable. On the basis of our modeling studies
Samuel Obeng et al.
European journal of pharmacology, 827, 32-40 (2018-03-14)
Evidence has shown that downstream signaling by mu opioid receptor (MOR) agonists that recruit β-arrestin2 may lead to the development of tolerance. Also, it has been suggested that opioid receptor desensitization and cyclic AMP overshoot contributes to the development of
Jeremy C Cornelissen et al.
European journal of pharmacology, 844, 175-182 (2018-12-16)
Mu-opioid receptor agonists are clinically effective analgesics, but also produce undesirable effects that limit their clinical utility. The nociceptin opioid peptide (NOP) receptor system also modulates nociception, and NOP agonists might be useful adjuncts to enhance the analgesic effects or
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service